Evidence map›Paper›PMID 42911315›Full record

ArticleInternational journal of clinical oncology2026

Patient-reported outcome sub-analysis of a phase 2 trial of bladder preservation therapy with atezolizumab and radiation therapy (BPT-ART) for invasive bladder cancer.

Bryan J Mathis, Yoshiyuki Nagumo, Tomokazu Kimura, Hitoshi Ishikawa, Yuta Sekino, Kazushi Maruo, Yukio Kageyama, Hiroki Ushijima, Jun Kamei, Hideomi Yamashita and 15 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Bryan J MathisDepartment of Cardiovascular Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Yoshiyuki NagumoDepartment of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan. ynagumo@gwe.md.tsukuba.ac.jp.ORCID http://orcid.org/0000-0003-0332-4791
Tomokazu KimuraDepartment of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hitoshi IshikawaDepartment of Radiation Oncology, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Yuta SekinoDepartment of Radiation Oncology and Proton Medical Research Center, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Kazushi MaruoTsukuba Clinical Research & Development Organization, University of Tsukuba, Tsukuba, Japan.
Yukio KageyamaDepartment of Urology, Saitama Cancer Center, Ina, Japan.
Hiroki UshijimaDepartment of Radiation Oncology, Saitama Cancer Center, Ina, Japan.
Jun KameiDepartment of Urology, The University of Tokyo, Bunkyo-ku, Japan.
Hideomi YamashitaDepartment of Radiation Oncology, The University of Tokyo, Bunkyo-ku, Japan.
Haruhito AzumaDepartment of Urology, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Japan.
Keiji NiheiDepartment of Radiation Oncology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Taku NaikiDepartment of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Natsuo TomitaDepartment of Radiology, Graduate School of Medical Sciences, Nagoya City University, Aichi, Japan.
Yasuyuki KobayashiDepartment of Urology, Okayama University Graduate School of Medicine, Okayama, Japan.
Kotaro YoshioDepartment of Proton Beam Therapy, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Takashi MatsumotoDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Tadamasa YoshitakeDepartment of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Takahiro OsawaDepartment of Urology, Hokkaido University, Sapporo, Japan.
Kentaro NishiokaDepartment of Radiation Medical Science and Engineering, Faculty of Medicine, Hokkaido University, Hokkaido, Japan.
Yuki KitaDepartment of Urology, Graduate School of Medicine and Faculty of Medicine, Kyoto University, Kyoto, Japan.
Takashi MizowakiDepartment of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Toyonori TsuzukiDepartment of Surgical Pathology Department, Aichi Medical University, Nagakute, Japan.
Koichi HashimotoTsukuba Clinical Research & Development Organization, University of Tsukuba, Tsukuba, Japan.
Hiroyuki NishiyamaDepartment of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

Funding

Chugai Pharmaceutical Chugai PharmaceuticalJapan Agency for Medical Research and Development JP256f0137008Japan Science and Technology Corporation JPMJPF2017
6 · The paper itself

Abstract

backgroundImpacts on quality of life (QoL) from bladder preservation therapy with atezolizumab and radiation therapy (BPT-ART), as assessed by patient reported outcomes (PROs), remains unanalyzed. We delineated temporal effects of BPT-ART on urinary QoL across multiple domains using established PRO tools.

methodsThis was a planned sub-analysis for the Phase 2 BPT-ART trial. PRO instruments included the EuroQol 5-item 5-point questionnaire (EQ-5D-5L), OABSS (Overactive Bladder Symptom Score) and IPSS (International Prostate Symptom Score). Forty-four total participants from 9 Japanese hospitals were surveyed from January 2019 to June 2024. Changes from baseline for each PRO tool were summarized over time as mean changes with 95% confidence intervals.

resultsEQ-5D-5L utility showed a transient decline during treatment, followed by recovery during follow-up. At the dimension level, pain/discomfort showed the largest transient decrease during radiotherapy (mean change - 0.60, 95% CI -0.90 to -0.31), followed by recovery after treatment. Total OABSS showed a modest increase during radiotherapy and recovered after treatment. Among OABSS components, urgency showed the largest increase (+ 0.95, 95% CI 0.44 to 1.46), followed by urgency incontinence (+ 0.53, 95% CI 0.11 to 0.96) and nighttime frequency (+ 0.33, 95% CI 0.04 to 0.62), while daytime frequency remained stable (+ 0.05, 95% CI -0.17 to 0.26). Baseline symptom burden was associated with absolute scores, but trajectories appeared comparable, and global health status remained stable across subgroups.

conclusionPROs outlined a temporal pattern of QoL decline but progressive recovery, as measured across patient-reported functional domains. These results support BPT-ART as effective for maintaining patient QoL.

Indexed as

Bladder cancerBladder preservation therapyBPT-ARTPatient reported outcomeQuality of life

Identifiers

PMID42911315

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.